{"title":"Cancer Vaccines: Mobilizing Immunity for Targeted Cancer Therapy.","authors":"Vural Yilmaz","doi":"10.31557/APJCP.2026.27.4.1171","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Cancer remains the leading cause of mortality in economically developed nations, presenting a major global health burden. Conventional anti-cancer therapies, such as chemotherapy and radiotherapy, often fall short of providing safe, targeted, and long-lasting treatments, particularly for aggressive and metastatic cancer types.</p><p><strong>Method: </strong>In recent years, cancer immunotherapy has emerged as a promising alternative that harnesses the patient's own immune system to recognize and eliminate malignant cells. Among the various immunotherapeutic strategies, cancer vaccines represent a dynamic and rapidly evolving field. These vaccines aim to stimulate or enhance tumor-specific immune responses and are tailored to target the diverse molecular and immunological hallmarks of cancer.</p><p><strong>Result: </strong>While several cancer vaccines have gained regulatory approval and entered clinical use, many others remain under investigation, requiring further optimization and evaluation through clinical trials.</p><p><strong>Conclusion: </strong>This review provides an overview of both clinically approved and emerging cancer vaccine strategies. Additionally, it examines the underlying factors that influence their clinical efficacy and translational potential, including immune evasion, delivery challenges, and patient-specific variables.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 4","pages":"1171-1178"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.4.1171","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Cancer remains the leading cause of mortality in economically developed nations, presenting a major global health burden. Conventional anti-cancer therapies, such as chemotherapy and radiotherapy, often fall short of providing safe, targeted, and long-lasting treatments, particularly for aggressive and metastatic cancer types.
Method: In recent years, cancer immunotherapy has emerged as a promising alternative that harnesses the patient's own immune system to recognize and eliminate malignant cells. Among the various immunotherapeutic strategies, cancer vaccines represent a dynamic and rapidly evolving field. These vaccines aim to stimulate or enhance tumor-specific immune responses and are tailored to target the diverse molecular and immunological hallmarks of cancer.
Result: While several cancer vaccines have gained regulatory approval and entered clinical use, many others remain under investigation, requiring further optimization and evaluation through clinical trials.
Conclusion: This review provides an overview of both clinically approved and emerging cancer vaccine strategies. Additionally, it examines the underlying factors that influence their clinical efficacy and translational potential, including immune evasion, delivery challenges, and patient-specific variables.
期刊介绍：
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
